Prostate Cancer Treatment Market Thumbnail Image

2020

Prostate Cancer Treatment Market

Prostate Cancer Treatment Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug Type and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2019-2026

LS : Pharmaceuticals

Select an option
Author's: Sayali Shinde | Roshan Deshmukh
Publish Date:

Get Sample to Email

The global prostate cancer treatment market size was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.

Prostate cancer is a type of cancer in which abnormal cells grow & invade in uncontrolled manner in the prostate gland. In term of cancer-related mortality in men, prostate cancer ranks sixth and eleventh in term of loss of life from any disease. Treatments of prostate cancer include radiation, surgery, chemotherapy, biological therapy, and hormone therapy. There are various diagnostic & therapeutic products used in the treatment & management of prostate cancer such as prostatic adenocarcinoma, benign prostatic hyperplasia, small cell carcinoma, and others. 

Prostate Cancer Treatment Market

Rise in geriatric population, increase in prevalence of prostate cancer, surge in generic products, rise in awareness among people regarding the treatment of prostate cancer, improved R&D investment by drug innovators, strong emerging pipeline drugs, and availability of new prostate cancer treatments are the major factors that drive the growth of the prostate cancer treatment market. In addition, increase in demand for prostate cancer treatment as well as management and rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings are other factors that contribute toward the growth of the market. Furthermore, untapped potential offered by the developing economies present lucrative opportunities for the growth of the market during the forecast period. However, prolonged treatment durations and poor demand for prostate cancer treatment drugs in underdeveloped countries are expected to hinder the growth of the market.    

Prostate Cancer Treatment Market Segmentation  

The prostate cancer treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, the market is categorized into chemotherapy, biological therapy, hormone therapy, and others. Depending on distribution channel, the market is classified into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment Review 

Based on drug type, the market is categorized into chemotherapy, biological therapy, and hormone therapy. Presently hormone therapy dominates the global prostate cancer treatment market, and is anticipated to continue this trend throughout the forecast period. The key factors that drive the market growth include increase in prevalence of prostate cancer, surge in demand for hormone therapy drugs, availability of generic drugs, rise in geriatric population, increase in number of pharmaceutical companies, and rise in public awareness toward prostate cancer treatment across the globe.

Prostate Cancer Treatment Market
By Drug Type
Your browser does not support the canvas element.

Hormone Therapy is projected as one of the most lucrative segment.

Based on distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Currently, the hospital pharmacies segment accounted for the majority of prostate cancer treatment market share, owing to strong presence of hospital pharmacies across the globe, increase in number of hospitalized prostate cancer patients, and convenience offered by hospital pharmacies. The online pharmacies is the fastest growing segment during the forecast period, owing to rise in awareness regarding online pharmacies, increase in number of internet users, and surge in preference for online purchasing of drugs over the traditional methods.

Prostate Cancer Treatment Market
By Distribution Channel
Your browser does not support the canvas element.

Hospital Pharmacy holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Snapshot of Asia-Pacific Prostate Cancer Treatment Market  

Asia-Pacific presents lucrative opportunities for the key players operating in the prostate cancer treatment market, owing to growth in awareness about prostate cancer treatment and rise in adoption of prostate cancer treatment products. Moreover, improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. Some of the other factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, high population base, and high disposable incomes are expected to drive the growth of the prostate cancer treatment market in Asia-Pacific.

Prostate Cancer Treatment Market
By Geography
2026
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 6.6% during 2019-2026.

The key players profiled in this report include Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson & Johnson, and Takeda Pharmaceutical Company Ltd.

Key Benefits for Stakeholders:

  • The study provides an in-depth analysis of the prostate cancer treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers prostate cancer treatment market analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and the global prostate cancer treatment market growth.

Key Market Segments:

By Drug Type 

  • Chemotherapy
  • Biological Therapy
  • Hormone Therapy
  • Others

By Distribution Channel 

  • Hospitals Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Prostate Cancer Treatment Market Report Highlights

Aspects Details
icon_5
By DRUG TYPE
  • Hormone Therapy
  • Biological Therapy
  • Chemotherapy
  • Others
icon_6
By ISTRIBUTION CHANNEL
  • Hospital pharmacy
  • Drug stores & retail pharmacy
  • Drug stores & retail pharmacy
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
icon_8
Key Market Players

Ferring Pharmaceuticals Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd, Ipsen Pharma, AstraZeneca plc, Bayer AG.

Analyst Review

Prostate cancer is a type of cancer that occurs in the prostate gland. It is one of the most common type of cancer in men. It is developed when cells in prostate gland starts multiplying uncontrollably. The average age of incidence is above 65 and rarely occurs below the age of 40. Treatments for prostate cancer include radiation therapy, surgery, and drug therapy. The drug therapy include chemotherapy, biological therapy, and hormone therapy.

Rise in prevalence of prostate cancer, technological advancements in prostate cancer treatment products, rise in number of pharmaceutical companies, strong emerging pipeline drugs, increase in popularity of hormone therapy drugs, and rise in demand for prostate cancer treatment products significantly boost the growth of the market. Moreover, rise in awareness among people regarding the treatments of prostate cancer, increase in number of generic products, surge in healthcare expenditure in the developed and developing regions, rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings, and improved R&D investment by drug innovators further fuel the growth of the global prostate cancer treatment market.

North America is expected to remain dominant during the forecast period, owing to higher adoption of prostate cancer treatment products with substantial presence of pharmaceutical and R&D laboratories. In addition, presence of advanced facilities and wide availability of advanced systems supplement the growth of the market. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to developments in infrastructure of the pharmaceutical industries along with rise in demand for prostate cancer treatment products.

 

Author Name(s) : Sayali Shinde | Roshan Deshmukh
Frequently Asked Questions?

The market value of global prostate cancer treatment market was $6,887.3 million in 2018.

The forecast period is from 2019 to 2026.

The market value of global prostate cancer treatment market in 2019 is $7,219.3 million.

The adoption of prostate cancer treatment is expected to increase due to Significant increase in prevalence of prostate cancer, rise in geriatric population, surge in awareness among people towards prostate cancer treatment, increase in demand for prostate cancer treatment products, and rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings majorly driving the market growth

The base year calculated in the report is 2018.

Yes, Bayer AG is profiled in the report.

Emerging countries of Asia-Pacific region are growing at a growth% of 6.6%. Japan, China, Australia, India, South Korea are expected grow at a CAGR of 6.4%, 7.6%, 5.7%, 7.2%, 6.0%, respectively.

The North America market held a major share in the prostate cancer treatment market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to surge in awareness among the population regarding early screening of cancer, increased adoption of prostate cancer treatment drugs, availability of premiere chemotherapy treatment options, and rise in non-government & government initiatives to promote healthcare are driving the prostate cancer treatment in North America

Loading Table Of Content...

Prostate Cancer Treatment Market

Global Opportunity Analysis and Industry Forecast, 2019-2026